monetization_vector
product sales / unit sales
Medium
SEC-10K 0000882095-26-000006
pricing_architecture
negotiated / tiered (with government discounts and rebates)
Medium
SEC-10K 0000882095-26-000006
target_gross_margin_bracket
20.1% Gross Margin (Moderate (20-40%))
High
SEC-XBRL
revenue_model_type
product sales / licensing
Medium
SEC-10K 0000882095-26-000006
customer_acquisition_metric
Direct physician/healthcare provider engagement via commercial sales teams and wholesaler distribution
Medium
SEC-10K 0000882095-26-000006
customer_segment_primary
institutional / government / healthcare providers
Medium
SEC-10K 0000882095-26-000006
customer_segment_secondary
government / institutional payers
Medium
SEC-10K 0000882095-26-000006
business_model_type_primary
biopharmaceutical manufacturer / product developer
Medium
SEC-10K 0000882095-26-000006
business_model_type_secondary
licensing / intellectual property monetization
Medium
SEC-10K 0000882095-26-000006
supply_chain_dependency
High
Medium
SEC-10K 0000882095-26-000006
headcount_cost_structure
Linear
Medium
SEC-10K 0000882095-26-000006
geographic_footprint
Global - primarily domestic (U.S.) with significant international exposure
Medium
SEC-10K 0000882095-26-000006
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
howey_test_risk_index
Low
Medium
SEC-10K 0000882095-26-000006
antitrust_exposure_flag
Yes
Medium
SEC-10K 0000882095-26-000006
data_sovereignty_risk
Moderate
Medium
SEC-10K 0000882095-26-000006
vendor_lock_dependency_score
High
Medium
SEC-10K 0000882095-26-000006
pricing_power_rating
Moderate
Medium
SEC-10K 0000882095-26-000006
network_effect_present
No
Medium
SEC-10K 0000882095-26-000006
switching_cost_profile
High
Medium
SEC-10K 0000882095-26-000006
asset_efficiency_ratio
16.6% Return on Assets (Excellent)
High
SEC-XBRL
recession_resistance_tier
Defensive
Medium
SEC-10K 0000882095-26-000006
interest_rate_sensitivity
Moderate
Medium
SEC-10K 0000882095-26-000006
debt_leverage_profile
1.22x Total Debt / Equity (Elevated leverage)
High
SEC-XBRL
geopolitical_supply_exposure
Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.
Medium
GICS-commodity-overlay-v2
marginal_cost_of_growth
Sublinear
Medium
SEC-10K 0000882095-26-000006
franchise_compliance_risk
N-A
Medium
SEC-10K 0000882095-26-000006
international_expansion_readiness
High
Medium
SEC-10K 0000882095-26-000006
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.25 (HIL — ~25% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v2
commodity_exposure_profile
Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.
Medium
GICS-commodity-overlay-v2
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
sec_cik
0000882095
High
SEC-EDGAR
ticker
GILD
High
SEC-EDGAR
capital_expenditure_profile
1.9% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
churn_vulnerability_index
Moderate
Medium
SEC-10K 0000882095-26-000006
Filings_Dog_Scope
antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,churn_vulnerability_index,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,data_sovereignty_risk,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,marginal_cost_of_growth,monetization_vector,network_effect_present,pricing_architecture,pricing_power_rating,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,supply_chain_dependency,switching_cost_profile,vendor_lock_dependency_score
High
SEC-10K 0000882095-26-000006
insider_buys_6m
0
High
SEC-Form4 0001638643-26-000035..0001782135-26-000014
insider_sells_6m
44
High
SEC-Form4 0001638643-26-000035..0001782135-26-000014
insider_net_shares_6m
-194000
High
SEC-Form4 0001638643-26-000035..0001782135-26-000014
insider_last_transaction_date
2026-10-01
High
SEC-Form4 0001638643-26-000035..0001782135-26-000014
Insider_Dog_Checked
2026-10-03T13:45|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m
High
SEC-Form4 registry
activist_13d_count_1y
0
Medium
SEC-13D/G registry, subject-verified
blockholder_13g_count_1y
3
Medium
SEC-13D/G registry, subject-verified
activist_last_13d_date
none in window
Medium
SEC-13D/G registry, subject-verified